Focused ultrasound enhances central nervous system delivery of Bevacizumab for malignant glioma treatment

Hao Li Liu, Po Hung Hsu, Chung Yin Lin, Chiun Wei Huang, Wen Yen Chai, Po Chun Chu, Chiung Yin Huang, Pin Yuan Chen, Liang Yo Yang, John S. Kuo, Kuo Chen Wei

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: To demonstrate that magnetic resonance (MR) imaging-monitored transcranial focused ultrasound can enhance the delivery of the antiangiogenic monoclonal antibody bevacizumab into the central nervous system (CNS) for glioblastoma multiforme (GBM) treatment. Materials and Methods: All animal experiments were approved by the animal committee and adhered to experimental animal care guidelines. Transcranial focused ultrasound exposure in the presence of microbubbles was used to open the bloodbrain barrier (BBB) to enhance bevacizumab penetration into the CNS in healthy and glioma-bearing mice. Bevacizumab concentration was quantitated with high-performance liquid chromatography, and Western blot testing was performed to confirm the specific biologic form in the CNS. Penetration of bevacizumab into brain tissue was estimated in vivo by means of contrast material-enhanced MR imaging and quantitative gallium 68 (68Ga)-bevacizumab micro-positron emission tomography, and glioma progression was longitudinally followed with T2-weighted MR imaging. Hematoxylin-eosin staining and cluster of differentiation 31 immunostaining were used to assess morphologic changes and vascular inhibition at histologic examination. The two-tailed Student t test and the Mantel-Cox log-rank test were used for statistical analyses, with a significance level of .05. Results: Focused ultrasound significantly enhanced bevacizumab penetration into the CNS by 5.7-to 56.7-fold compared with that in nonexposed brain (both P<.0001). Contrast-enhanced MR imaging indexes correlated with bevacizumab concentration (r = 0.748-0.857) in vivo. Focused ultrasound-enhanced bevacizumab delivery significantly retarded glioma progression, with a significantly increased median survival (median increase in survival time = 135% in the group treated with bevacizumab and focused ultrasound, P<.0001; as compared with 48% in the group treated with bevacizumab alone, P = .0002). Conclusion: Focused ultrasound-enhanced bevacizumab delivery can provide an antivascularization normalization effect to suppress glioma.

Original languageEnglish
Pages (from-to)99-108
Number of pages10
JournalRadiology
Volume281
Issue number1
DOIs
Publication statusPublished - Oct 1 2016
Externally publishedYes

Fingerprint

Glioma
Central Nervous System
Magnetic Resonance Imaging
Therapeutics
Bevacizumab
Microbubbles
Gallium
Survival
Brain
Hematoxylin
Glioblastoma
Eosine Yellowish-(YS)
Positron-Emission Tomography
Contrast Media
Blood Vessels
Western Blotting
High Pressure Liquid Chromatography
Monoclonal Antibodies
Guidelines
Staining and Labeling

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Liu, H. L., Hsu, P. H., Lin, C. Y., Huang, C. W., Chai, W. Y., Chu, P. C., ... Wei, K. C. (2016). Focused ultrasound enhances central nervous system delivery of Bevacizumab for malignant glioma treatment. Radiology, 281(1), 99-108. https://doi.org/10.1148/radiol.2016152444

Focused ultrasound enhances central nervous system delivery of Bevacizumab for malignant glioma treatment. / Liu, Hao Li; Hsu, Po Hung; Lin, Chung Yin; Huang, Chiun Wei; Chai, Wen Yen; Chu, Po Chun; Huang, Chiung Yin; Chen, Pin Yuan; Yang, Liang Yo; Kuo, John S.; Wei, Kuo Chen.

In: Radiology, Vol. 281, No. 1, 01.10.2016, p. 99-108.

Research output: Contribution to journalArticle

Liu, HL, Hsu, PH, Lin, CY, Huang, CW, Chai, WY, Chu, PC, Huang, CY, Chen, PY, Yang, LY, Kuo, JS & Wei, KC 2016, 'Focused ultrasound enhances central nervous system delivery of Bevacizumab for malignant glioma treatment', Radiology, vol. 281, no. 1, pp. 99-108. https://doi.org/10.1148/radiol.2016152444
Liu, Hao Li ; Hsu, Po Hung ; Lin, Chung Yin ; Huang, Chiun Wei ; Chai, Wen Yen ; Chu, Po Chun ; Huang, Chiung Yin ; Chen, Pin Yuan ; Yang, Liang Yo ; Kuo, John S. ; Wei, Kuo Chen. / Focused ultrasound enhances central nervous system delivery of Bevacizumab for malignant glioma treatment. In: Radiology. 2016 ; Vol. 281, No. 1. pp. 99-108.
@article{2ba669b0430f4a2595066819cbf8e79e,
title = "Focused ultrasound enhances central nervous system delivery of Bevacizumab for malignant glioma treatment",
abstract = "Purpose: To demonstrate that magnetic resonance (MR) imaging-monitored transcranial focused ultrasound can enhance the delivery of the antiangiogenic monoclonal antibody bevacizumab into the central nervous system (CNS) for glioblastoma multiforme (GBM) treatment. Materials and Methods: All animal experiments were approved by the animal committee and adhered to experimental animal care guidelines. Transcranial focused ultrasound exposure in the presence of microbubbles was used to open the bloodbrain barrier (BBB) to enhance bevacizumab penetration into the CNS in healthy and glioma-bearing mice. Bevacizumab concentration was quantitated with high-performance liquid chromatography, and Western blot testing was performed to confirm the specific biologic form in the CNS. Penetration of bevacizumab into brain tissue was estimated in vivo by means of contrast material-enhanced MR imaging and quantitative gallium 68 (68Ga)-bevacizumab micro-positron emission tomography, and glioma progression was longitudinally followed with T2-weighted MR imaging. Hematoxylin-eosin staining and cluster of differentiation 31 immunostaining were used to assess morphologic changes and vascular inhibition at histologic examination. The two-tailed Student t test and the Mantel-Cox log-rank test were used for statistical analyses, with a significance level of .05. Results: Focused ultrasound significantly enhanced bevacizumab penetration into the CNS by 5.7-to 56.7-fold compared with that in nonexposed brain (both P<.0001). Contrast-enhanced MR imaging indexes correlated with bevacizumab concentration (r = 0.748-0.857) in vivo. Focused ultrasound-enhanced bevacizumab delivery significantly retarded glioma progression, with a significantly increased median survival (median increase in survival time = 135{\%} in the group treated with bevacizumab and focused ultrasound, P<.0001; as compared with 48{\%} in the group treated with bevacizumab alone, P = .0002). Conclusion: Focused ultrasound-enhanced bevacizumab delivery can provide an antivascularization normalization effect to suppress glioma.",
author = "Liu, {Hao Li} and Hsu, {Po Hung} and Lin, {Chung Yin} and Huang, {Chiun Wei} and Chai, {Wen Yen} and Chu, {Po Chun} and Huang, {Chiung Yin} and Chen, {Pin Yuan} and Yang, {Liang Yo} and Kuo, {John S.} and Wei, {Kuo Chen}",
year = "2016",
month = "10",
day = "1",
doi = "10.1148/radiol.2016152444",
language = "English",
volume = "281",
pages = "99--108",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Focused ultrasound enhances central nervous system delivery of Bevacizumab for malignant glioma treatment

AU - Liu, Hao Li

AU - Hsu, Po Hung

AU - Lin, Chung Yin

AU - Huang, Chiun Wei

AU - Chai, Wen Yen

AU - Chu, Po Chun

AU - Huang, Chiung Yin

AU - Chen, Pin Yuan

AU - Yang, Liang Yo

AU - Kuo, John S.

AU - Wei, Kuo Chen

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Purpose: To demonstrate that magnetic resonance (MR) imaging-monitored transcranial focused ultrasound can enhance the delivery of the antiangiogenic monoclonal antibody bevacizumab into the central nervous system (CNS) for glioblastoma multiforme (GBM) treatment. Materials and Methods: All animal experiments were approved by the animal committee and adhered to experimental animal care guidelines. Transcranial focused ultrasound exposure in the presence of microbubbles was used to open the bloodbrain barrier (BBB) to enhance bevacizumab penetration into the CNS in healthy and glioma-bearing mice. Bevacizumab concentration was quantitated with high-performance liquid chromatography, and Western blot testing was performed to confirm the specific biologic form in the CNS. Penetration of bevacizumab into brain tissue was estimated in vivo by means of contrast material-enhanced MR imaging and quantitative gallium 68 (68Ga)-bevacizumab micro-positron emission tomography, and glioma progression was longitudinally followed with T2-weighted MR imaging. Hematoxylin-eosin staining and cluster of differentiation 31 immunostaining were used to assess morphologic changes and vascular inhibition at histologic examination. The two-tailed Student t test and the Mantel-Cox log-rank test were used for statistical analyses, with a significance level of .05. Results: Focused ultrasound significantly enhanced bevacizumab penetration into the CNS by 5.7-to 56.7-fold compared with that in nonexposed brain (both P<.0001). Contrast-enhanced MR imaging indexes correlated with bevacizumab concentration (r = 0.748-0.857) in vivo. Focused ultrasound-enhanced bevacizumab delivery significantly retarded glioma progression, with a significantly increased median survival (median increase in survival time = 135% in the group treated with bevacizumab and focused ultrasound, P<.0001; as compared with 48% in the group treated with bevacizumab alone, P = .0002). Conclusion: Focused ultrasound-enhanced bevacizumab delivery can provide an antivascularization normalization effect to suppress glioma.

AB - Purpose: To demonstrate that magnetic resonance (MR) imaging-monitored transcranial focused ultrasound can enhance the delivery of the antiangiogenic monoclonal antibody bevacizumab into the central nervous system (CNS) for glioblastoma multiforme (GBM) treatment. Materials and Methods: All animal experiments were approved by the animal committee and adhered to experimental animal care guidelines. Transcranial focused ultrasound exposure in the presence of microbubbles was used to open the bloodbrain barrier (BBB) to enhance bevacizumab penetration into the CNS in healthy and glioma-bearing mice. Bevacizumab concentration was quantitated with high-performance liquid chromatography, and Western blot testing was performed to confirm the specific biologic form in the CNS. Penetration of bevacizumab into brain tissue was estimated in vivo by means of contrast material-enhanced MR imaging and quantitative gallium 68 (68Ga)-bevacizumab micro-positron emission tomography, and glioma progression was longitudinally followed with T2-weighted MR imaging. Hematoxylin-eosin staining and cluster of differentiation 31 immunostaining were used to assess morphologic changes and vascular inhibition at histologic examination. The two-tailed Student t test and the Mantel-Cox log-rank test were used for statistical analyses, with a significance level of .05. Results: Focused ultrasound significantly enhanced bevacizumab penetration into the CNS by 5.7-to 56.7-fold compared with that in nonexposed brain (both P<.0001). Contrast-enhanced MR imaging indexes correlated with bevacizumab concentration (r = 0.748-0.857) in vivo. Focused ultrasound-enhanced bevacizumab delivery significantly retarded glioma progression, with a significantly increased median survival (median increase in survival time = 135% in the group treated with bevacizumab and focused ultrasound, P<.0001; as compared with 48% in the group treated with bevacizumab alone, P = .0002). Conclusion: Focused ultrasound-enhanced bevacizumab delivery can provide an antivascularization normalization effect to suppress glioma.

UR - http://www.scopus.com/inward/record.url?scp=84989237497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989237497&partnerID=8YFLogxK

U2 - 10.1148/radiol.2016152444

DO - 10.1148/radiol.2016152444

M3 - Article

C2 - 27192459

AN - SCOPUS:84989237497

VL - 281

SP - 99

EP - 108

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -